## Who to refer?

### Based on FH e.g. in one stop

The following women should be referred to Clinical Genetics for an assessment about their eligibility for additional breast screening. A woman with:

- A first degree relative (FDR) with breast cancer under the age of 40
- A first degree relative with male breast cancer
- Two first degree relatives with breast cancer
- One first and one second degree relative with breast cancer
- One first degree relative with bilateral breast cancer
- One relative with breast cancer and one with ovarian cancer (one must be first degree)
- Two relatives with ovarian cancer
- Three or more relatives with breast or ovarian cancer

#### **Notes**

- 1. If the consultee has breast cancer and residual breast tissue, count as a FDR
- 2. An affected female second degree relative through a male relative is equivalent to an FDR

In a nutshell – one breast >40 **OR** one ovarian cancer doesn't meet referral criteria – everything else does

### Who to refer?

### New cancer diagnosis

# Does the individual with breast cancer (<u>including high grade DCIS</u>) meet one of the following criteria?

- Breast cancer <40 years, OR</li>
- HER2 positive breast cancer, age 31-35 years, OR
- Bilateral breast cancer, both < 60 years, OR</li>
- Triple negative breast cancer < 60 years, OR</li>
- Male/assigned male at birth and breast cancer at any age, OR
- High grade non-mucinous ovarian cancer at any age, OR
- Breast cancer <45 years and a first degree relative (FDR) with breast cancer < 45 years, OR</li>
- Ashkenazi Jewish ancestry, OR
- 1 or more grandparents from Westray (Orkney) or Whalsay (Shetland)

OR MANCHESTER SCORE 15+

# Risk groups

Population

Moderate

High

Very High

family history

family history

gene carriers

Screening; (chemoprophylaxis)

Screening; Chemoprophylaxis; (Surgical risk reduction)

Screening; Chemoprophylaxis; Surgical risk reduction

## Aims of genetic testing after bc diagnosis

#### **Short term**

- To know whether the patient carries a 'very high' risk breast cancer gene change
- To guide risk estimates of developing a second separate breast cancer over their lifetime
- May influence primary surgical and radiotherapy decisions
- Avoidance of radiotherapy in TP53 carriers

#### Longer term

- Is there a high risk of associated cancers for which screening or risk reducing options are available?
- To guide information and advice to other family members

#### **Future**

To guide chemotherapeutic options



## Genetic testing in breast cancer



<sup>\*</sup>ATM, CHEK2, PTEN, TP53, STK11

## **DNA** storage

DNA can be extracted from a blood sample and stored for many years in our lab

Then potentially used in the future (with patient's explicit consent) to activate specific genetic tests

Useful for urgent samples and/or for patients who might prefer a telephone appointment with us; or for terminally ill patients to benefit their families.

Need approx. 3mls purple (EDTA) tube in the form below – **need to tell patient this is not being tested – just stored** 

